[Federal Register Volume 85, Number 197 (Friday, October 9, 2020)]
[Notices]
[Page 64165]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-22442]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-720]


Bulk Manufacturer of Controlled Substances Application: Purisys, 
LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Purisys, LLC has applied to be registered as a bulk 
manufacturer of basic class(es) of controlled substance(s). Refer to 
Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before December 8, 
2020. Such persons may also file a written request for a hearing on the 
application on or before December 8, 2020

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this 
is notice that on August 27, 2020, Purisys, LLC, 1550 Olympic Drive, 
Athens, Georgia 30601-1602, applied to be registered as an bulk 
manufacturer of the following basic class(es) of controlled substances:

------------------------------------------------------------------------
        Controlled substance            Drug code          Schedule
------------------------------------------------------------------------
5-Methoxy-N-N-dimethyltryptamine...            7431  I
Norlevorphanol.....................            9634  I
------------------------------------------------------------------------

    The company plans to manufacture the above-listed controlled 
substances as clinical trial and starting materials to make compounds 
for distribution to its customers. No other activity for these drug 
codes is authorized for this registration.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-22442 Filed 10-8-20; 8:45 am]
BILLING CODE P